- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Fischer receives FDA warning letter
Fischer Imaging of Denver received a warning letter from the Food and Drug Administration last month for deficiencies in its manufacturing documentation processes. The notification is the second time in two years that Fischer has received a warning
Fischer Imaging of Denver received a warning letter from the Food and Drug Administration last month for deficiencies in its manufacturing documentation processes. The notification is the second time in two years that Fischer has received a warning letter from the agency (SCAN 5/10/95).
The warning letter follows a six-week FDA inspection that took place late last year as part of a routine biennial audit of Fischer's manufacturing facility, according to Sammy Emrich, director of regulatory affairs at Fischer. In the letter, the FDA expressed concern with manufacturing documentation, as well as the methods Fischer uses to determine trends in its manufacturing process.
Fischer is responding to the letter by improving its documentation processes, examining better system reporting, and establishing product improvement teams, Emrich said. The FDA did not find fault with Fischer's products or the manufacturing process itself, she said.
In the warning letter Fischer received two years ago, the FDA cited Fischer for improper follow-up on repairs, inadequate analysis of product failures, and assigning to a single employee both quality assurance and manufacturing functions. Fischer complied with FDA concerns in that case, and the most recent letter commented on some of the improvements Fischer made in response to the first letter.
CT Study Reveals Key Indicators for Angiolymphatic Invasion in Non-Small Cell Lung Cancer
January 15th 2025In computed tomography (CT) scans for patients with solid non-small cell lung cancer (NSCLC) < 30 mm, emerging research suggests the lollipop sign is associated with a greater than fourfold likelihood of angiolymphatic invasion.
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.
Shaping the Future of Radiology in 2025: Trends, Threats, and Opportunities
January 10th 2025How do we respond to challenges with staff recruitment, cybersecurity, and looming hospital takeovers in radiology? This author assesses key trends in radiology and offers key insights to stay competitive in the field.
